“Comprehensive” Drug Shortage Mitigation Bill Under Development In House
Executive Summary
Like the Senate proposal, it could include reimbursement rate adjustments in addition to requiring early notification of shortages by manufacturers, but questions remain about ensuring there are no unintended consequences.
You may also be interested in...
Drug Shortage Bill In House Refines Hatch Reimbursement Proposal
Sterile injectable products with three or fewer manufacturers would get better federal reimbursement rates in an effort to attract more producers to the market; H.R. 6611 was modeled after a similar proposal from Sen. Orrin Hatch, R-Utah.
Drug Shortages Proposal From Sen. Hatch Offers 7-Year Economic Incentives
The Utah Republican’s draft bill would encourage industry to increase its capacity to manufacture sterile injectable drug products by providing higher reimbursement rates and exclusivity incentives. House Republicans continue to pursue economic options, but time and jurisdictional factors could work against such measures to address shortages.
Drug Shortages Proposal From Sen. Hatch Offers 7-Year Economic Incentives
The Utah Republican’s draft bill would provide higher reimbursement rates for sterile injectable products and provide exclusivity incentives. House Republicans continue to pursue economic options, but time and jurisdictional factors could work against such measures to address shortages.